Effect of the vascular endothelial growth factor expression level on angiopoietin-2-mediated nasopharyngeal carcinoma growth

Vascular Cell

Volumn 6, Issue 1, 2014, Pages

  Chen, Hai Hong ^a   Weng, Bin Qi ^a   Cheng, Ke Jia ^a   Liu, Hong Yan ^a   Wang, Shen Qing ^a   Lu, Yv Yv ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiopoietin 2; Nasopharyngeal carcinoma; Tumor angiogenesis; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; LIPOSOME; MICRORNA; VASCULOTROPIN;

ANGIOGENESIS; CANCER GROWTH; CAPILLARY DENSITY; CARCINOGENICITY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION;

MUS MUSCULUS;

EID: 84897996355     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-6-4     Document Type: Review

References (25)

1. Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway. Imanishi Y, Hu B, Xiao G, Yao X, Cheng SY, J Biol Chem 2011 286 29249 29260 10.1074/jbc.M111.235689 21680733
2. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y, Int J Oncol 2012 40 1321 1330 22327175
3. 1 integrin-mediated pathway. Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, Cheng SY, Cancer Res 2007 67 4254 4263 10.1158/0008-5472.CAN-06-4100 17483337 (Pubitemid 46815072)
4. Angiopoietin-2 promotes disease progression of neuroendocrine tumor. Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M, Scholz A, Clin Cancer Res 2010 16 420 429 10.1158/1078-0432.CCR-09- 1924 20068079
5. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Lakely B, Fanslow WC, True LD, Corey E, Vessella RL, Prostate 2010 70 1799 1808 20583134
6. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, Shaheen RM, Bucana CD, Ellis LM, Cancer Res 2021 61 1255 1259
7. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C, Neoplasia 2006 8 419 428 10.1593/neo.06109 16790091 (Pubitemid 43830749)
8. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Yu Q, Stamenkovic I, Am J Pathol 2001 158 563 570 10.1016/S0002-9440(10)63998-3 11159193 (Pubitemid 32158617)
9. The effects of angiopoietin-2 on the growth of tongue carcinoma. Chen HH, Shi ZJ, Wang SQ, Wu QL, Br J Oral Maxillofac Surg 2009 47 14 19 10.1016/j.bjoms.2008.06.008 18706742
10. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, Li CY, Kontos CD, Dewhirst MW, Cancer Res 2007 67 3835 3844 10.1158/0008-5472.CAN-06-4056 17440098 (Pubitemid 46762171)
11. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H, Cancer Res 2002 62 7124 7129 12460935 (Pubitemid 35424109)
12. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G, Cancer Res 2013 78 108 118
13. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, Bready JV, Oliner JD, McDonald DM, Cancer Res 2010 70 2213 2223 10.1158/0008-5472.CAN-09-1977 20197469
14. Trends in nasopharyngeal carcinoma mortality in China, 1973-2005. Huang TR, Zhang SW, Chen WQ, Deng W, Zhang CY, Zhou XJ, Zhai RH, Asian Pac J Cancer Prev 2012 13 2495 2502 10.7314/APJCP.2012.13.6.2495 22938411
15. Ancient migration routes of Austronesian-speaking populations in oceanic Southeast Asia and Melanesia might mimic the spread of nasopharyngeal carcinoma. Trejaut J, Lee CL, Yen JC, Loo JH, Lin M, Chin J Cancer 2011 30 96 105 10.5732/cjc.010.10589 21272441
16. Combination of pigment epithelium-derived factor with radiotherapy enhances the antitumor effects on nasopharyngeal carcinoma by downregulating vascular endothelial growth factor expression and angiogenesis. Xu Z, Fang S, Zuo Y, Zhang Y, Cheng R, Wang Q, Yang Z, Cai W, Ma J, Yang X, Gao G, Cancer Sci 2011 102 1789 1798 10.1111/j.1349-7006.2011.02013.x 21707863
17. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma. Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y, Chen J, Hu X, Zhou Q, Wang Y, Ma H, Bao Y, Chen M, PLoS One 2012 7 34646 10.1371/journal.pone.0034646 22496834
18. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Guang-Wu H, Sunagawa M, Jie-En L, Shimada S, Gang Z, Tokeshi Y, Kosugi T, Laryngoscope 2000 110 2066 2069 10.1097/00005537-200012000-00017 11129022
19. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. Li YH, Hu CF, Shao Q, Huang MY, Hou JH, Xie D, Zeng YX, Shao JY, J Transl Med 2008 6 1 11 10.1186/1479-5876-6-1 18171482 (Pubitemid 351325348)
20. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. Weidner N, Semple JP, Welch WR, Folkman J, N Engl J Med 1991 324 1 8 10.1056/NEJM199101033240101
21. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M, Cancer Res 2001 61 2145 2153 11280779 (Pubitemid 32692040)
22. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR, J Clin Invest 1999 103 341 345 10.1172/JCI4891 9927494 (Pubitemid 29069983)
23. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, Fukumura D, Clin Cancer Res 2010 16 3618 3627 10.1158/1078-0432.CCR-09-3073 20501615
24. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Uemura M, Masaki T, Fukui H, Gut 2005 54 1768 1775 10.1136/gut.2005.067900 16033879 (Pubitemid 41697677)
25. Angiopoietin-2 stimulates migration of endothelial progenitors and their interaction with endothelium. Gill KA, Brindle NP, Biochem Biophys Res Commun 2005 336 392 396 10.1016/j.bbrc.2005.08.097 16129411 (Pubitemid 41268664)